Research programme: acromegaly therapeutics - Ipsen Bioinnovation

Drug Profile

Research programme: acromegaly therapeutics - Ipsen Bioinnovation

Alternative Names: SXN 101959

Latest Information Update: 17 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntaxin
  • Developer Ipsen Bioinnovation
  • Class Bacterial toxins; Botulinum toxins; Recombinant proteins
  • Mechanism of Action Growth hormone releasing factor agonists; Pituitary hormone inhibitors; SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acromegaly

Most Recent Events

  • 24 Jul 2013 SXN 101959 is still in preclinical development for Acromegaly in the United Kingdom
  • 15 Jul 2013 Ipsen acquires Syntaxin
  • 31 Jul 2009 Preclinical trials in Acromegaly in the United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top